Advertisement
Screener

Definium Therapeutics, Inc. (DFTX) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2.2 / 5 stars · 23/52 Roast Me

Definium Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.41 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06

  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.05M shares, a 10.61% decline year-over-year.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 357.61K shares, a 52.67% decline year-over-year.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 332.35K shares, a 40.48% decline year-over-year.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 783.40K shares, a 179.99% increase year-over-year.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.05M shares, a 16.13% increase from fiscal 2024.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.63M shares.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 990.01K shares, a 95.10% decline from fiscal 2021.
  • Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 20.19M shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month
2026-06-301.05M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
1.41M shares
10-Q · filed 2026-08-06
1.74M shares
derived: sum of 3 quarters · filed 2026-08-06
2.53M shares
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31357.61K shares
10-Q · filed 2026-05-07
689.96K shares
derived: sum of 2 quarters · filed 2026-05-07
1.47M shares
derived: sum of 3 quarters · filed 2026-05-07
2.65M shares
derived: sum of 4 quarters · filed 2026-05-07
2025-12-31332.35K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
1.12M shares
derived: sum of 2 quarters · filed 2026-02-26
2.30M shares
derived: sum of 3 quarters · filed 2026-02-26
3.05M shares
10-K · filed 2026-02-26
2025-09-30783.40K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
1.96M shares
derived: sum of 2 quarters · filed 2025-11-06
2.72M shares
10-Q · filed 2025-11-06
3.28M shares
derived: sum of 4 quarters · filed 2025-11-06
2025-06-301.18M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31
1.94M shares
10-Q · filed 2025-07-31
2.49M shares
derived: sum of 3 quarters · filed 2025-07-31
2.77M shares
derived: sum of 4 quarters · filed 2025-07-31
2025-03-31755.50K shares
10-Q · filed 2025-05-08
1.31M shares
derived: sum of 2 quarters · filed 2025-05-08
1.59M shares
derived: sum of 3 quarters · filed 2025-05-08
1.68M shares
derived: sum of 4 quarters · filed 2025-05-08
2024-12-31558.40K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06
838.20K shares
derived: sum of 2 quarters · filed 2025-03-06
920.73K shares
derived: sum of 3 quarters · filed 2025-03-06
2.63M shares
10-K · filed 2025-03-06
2024-09-30279.80K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
362.33K shares
derived: sum of 2 quarters · filed 2024-11-07
2.07M shares
10-Q · filed 2024-11-07
2024-06-3082.53K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
1.79M shares
10-Q · filed 2024-08-13
2024-03-311.71M shares
10-Q · filed 2024-05-08
2022-12-3130.41K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
-9.39M shares
derived: sum of 2 quarters · filed 2023-03-09
-7.37M shares
derived: sum of 3 quarters · filed 2023-03-09
990.01K shares
10-K · filed 2023-03-09
2022-09-30-9.42M shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-7.40M shares
derived: sum of 2 quarters · filed 2022-11-10
959.61K shares
10-Q · filed 2022-11-10
2022-06-302.02M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
10.38M shares
10-Q · filed 2022-08-11
2022-03-318.36M shares
10-Q · filed 2022-05-16
2021-12-3120.19M shares
10-K · filed 2022-03-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cronos Group Inc. (CRON)$1.223B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Canopy Growth Corp (CGC)$0.395B
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
Niagen Bioscience, Inc. (NAGE)United States$0.238B15.72
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B